| Identification | Back Directory | [Name]
(3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol | [CAS]
156722-18-8 | [Synonyms]
CS-906
PST2238
17-triol
AC1L4BGU
Rostafuroxin
CHEMBL2068971
SureCN1716210
UNII-P848LCX62B
PST 2238, >=98%
PST2238,Rostafuroxin
Rostafuroxin PST2284
Rostafuroxin (PST-2238)
17-(3-Furyl)-5beta-androstane-3
17-β-(3-furyl)-5-β-androstane-3-β, 14-β, 17-α-triol
(3β,5β,14β)-21,23-Epoxy-24-Norchola-20,22-diene-3,14,17-triol
24-Norchola-20,22-diene-3,14,17-triol, 21,23-epoxy-, (3β,5β,14β)-
(3beta,5beta,14beta)-21,23-Epoxy-24-norchola-20,22-diene-3,14,17-triol
Rostafuroxin
(3beta,5beta,14beta)-21,23-Epoxy-24-norchola-20,22-diene-3,14,17-triol
(3beta,5beta,14beta)-21,23-Epoxy-24-norchola-20,22-diene-3,14,17-triol Rostafuroxin (PST 2238)
PST 2238; PST-2238; AC1L4BGU; SURECN1716210; UNII-P848LCX62B; 17-(3-FURYL)-5BETA-ANDROSTANE-3;14;17-TRIOL; CHEMBL2068971; 156722-18-8
(3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol | [Molecular Formula]
C23H34O4 | [MDL Number]
MFCD00927279 | [MOL File]
156722-18-8.mol | [Molecular Weight]
374.51 |
| Chemical Properties | Back Directory | [Boiling point ]
451.3±45.0 °C(Predicted) | [density ]
1.226±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
insoluble in H2O; insoluble in EtOH; ≥12.05 mg/mL in DMSO | [form ]
solid | [pka]
14.02±0.70(Predicted) |
| Hazard Information | Back Directory | [Description]
Rostafuroxin potently inhibits binding of endogenous ouabain to the Na+/K+ ATPase (IC50 = 1.7 μM) through the Src-epidermal growth factor receptor (EGFR)-dependent signaling pathway. This blocks the ouabain-dependent increase in Na+/K+ ATPase activity. In cultured renal cells where the Na+/K+ ATPase is upregulated or has increased activity, rostafuroxin normalizes mRNA levels and Na+/K+ ATPase activity. At very low doses (1 and 10 μg/kg for 5-6 weeks) in Milan-hypertensive rats, it decreased the development of hypertension. In a Phase II clinical study, rostafuroxin did not reduce blood pressure in human patients at doses of 0.05-5.0 mg/d. | [Uses]
(3β,5β,14β)-21,23-Epoxy-24-Norchola-20,22-diene-3,14,17-triol is used as a receptor blocker in the treatment of hypertension. | [in vitro]
at molecular level, in the kidney, rostafuroxin antagonizes eo by triggering of the src-epidermal growth factor receptor (egfr)-dependent signaling pathway leading to renal na+-k+ pump, and erk tyrosine phosphorylation and activation. in the vasculature, it normalizes the increased myogenic tone caused by nanomolar ouabain [1]. | [in vivo]
rostafuroxin reduces blood pressure without affecting heart rate, and restores the normal activity of the renal na+-k+-atpase in mhs rats when orally treated at doses from 1 to 100 μg/kg/day. similarly, nua rats have their blood pressure normalized by rostafuroxin [1]. | [IC 50]
2 μm for na+-k+-atpase | [storage]
Store at -20°C | [References]
[1] ferrari p, ferrandi m, valentini g, bianchi g. rostafuroxin: an ouabain antagonist that corrects renal and vascular na+-k+-atpase alterations in ouabain and adducin-dependent hypertension. am j physiol regul integr comp physiol. 2006 mar;290(3):r529-35. |
| Spectrum Detail | Back Directory | [Spectrum Detail]
(3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol(156722-18-8)1HNMR
|
|
|